Abstract: INFO15-TH
CAPTIVATE: A Global Adaptive Platform Trial for Adults with CKD
Session Information
- Informational Posters - 1
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- No subcategory defined
Authors
- Kotwal, Sradha S., The George Institute for Global Health, Sydney, New South Wales, Australia
- Shah, Nasir A., The George Institute for Global Health, Sydney, New South Wales, Australia
- Arnott, Clare Gabrielle, The George Institute for Global Health, Sydney, New South Wales, Australia
- Billot, Laurent, The George Institute for Global Health, Sydney, New South Wales, Australia
- Birne, Rita, Associacao Protectora dos Diabeticos de Portugal, Lisbon, Portugal
- de Boer, Ian, University of Washington, Seattle, Washington, United States
- De Nicola, Luca, Universita degli Studi della Campania Luigi Vanvitelli, Caserta, Campania, Italy
- de Silva, Asita, Clinical Trials Unit, Faculty of Medicine, University of Kelaniya, Colombo, Sri Lanka
- de Zoysa, Janak, Te Whatu Ora Health New Zealand Waitemata, Auckland, New Zealand
- Di Tanna, Gian Luca, University of Applied Sciences and Arts of Southern Switzerland, Manno, Switzerland
- Gorriz, Jose L., Hospital Clínico Universitario de Valencia, Valencia, Spain
- Gray, Nicholas A., Sunshine Coast Hospital and Health Service, Nambour, Queensland, Australia
- Guinness, Dean, The George Institute for Global Health, Sydney, New South Wales, Australia
- Hansen, Abigail, The George Institute for Global Health, Sydney, New South Wales, Australia
- Jardine, Meg, NHMRC Clinical Trials Centre, Camperdown, New South Wales, Australia
- Jha, Vivekanand, The George Institute for Global Health India, New Delhi, DL, India
- Kim, Dana, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia
- Krishnasamy, Rathika, Sunshine Coast Hospital and Health Service, Nambour, Queensland, Australia
- Lim, Soo Kun, Universiti Malaya Pusat Perubatan, Federal Territory of Kuala Lumpur, Malaysia
- Lin, Enmoore, The George Institute for Global Health, Sydney, New South Wales, Australia
- Monaghan, Helen, The George Institute for Global Health, Sydney, New South Wales, Australia
- Perkovic, Vlado, University of New South Wales, Sydney, New South Wales, Australia
- Philip, Krupa, The George Institute for Global Health, Sydney, New South Wales, Australia
- Sarafidis, Pantelis, Aristoteleio Panepistemio Thessalonikes, Thessaloniki, Greece
- Heerspink, Hiddo Jan L., The George Institute for Global Health, Sydney, Australia
Group or Team Name
- on behalf of the CAPTIVATE investigators
Description
Background: Chronic kidney disease (CKD) is a major health burden associated with cardiovascular events, mortality, and progression to kidney failure. Efficient, scalable trials are needed to evaluate therapies that slow CKD progression while preserving flexibility as standards of care evolve.
Description: CAPTIVATE (The Chronic kidney disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect) is an ongoing Phase III, multicenter, placebo-controlled, adaptive platform trial coordinated by The George Institute for Global Health and supported by multiple funding partners (NCT06058585). The platform evaluates investigational agents, alone or in combination, in adults with CKD receiving standard-of-care therapy. The primary objective is to identify therapies that slow chronic eGFR decline. Secondary outcomes include albuminuria, kidney failure, cardiovascular events, mortality, safety/tolerability, and quality of life through 108 weeks.
Enrollment opportunity: The active mineralocorticoid receptor antagonist (MRA) domain compares finerenone 10/20 mg with matched placebo to week 104. Two additional domains, evaluating a GLP-1 receptor agonist and an endothelin receptor antagonist are pending, enabling eligible participants to be randomized concurrently across multiple treatment domains within the adaptive platform.
Current status: As of June 9, 2026, the MRA domain had 46 active sites worldwide: India (18), Australia (13), Sri Lanka (8), New Zealand (6), and Spain (1), with 24 additional sites planned in 2026. Overall, 560/1000 participants had been randomized.
Conclusion: CAPTIVATE illustrates how adaptive platform trials can use a modular infrastructure to evaluate multiple therapies at the same time efficiently, flexibly, and potentially more cost-effectively than sequential trials. By allowing treatment domains to be added over time and enabling participants to contribute to more than one intervention concurrently, CAPTIVATE provides an international enrollment platform to accelerate assessment of kidney-protective therapies.
Funding
- 1) Seed funding through The George Institute for Global Health 2) Australian Government National Health and Medical Research Council (NHMRC) Clinical Trials and Cohort Studies grant (Grant Identification Number 2024079).